A Potential Breakthrough in the Treatment of Glaucoma: Implant May Change Paradigm of Treatment
June 21, 2011
In a news release on June 14th, pSivida announced the commencement of a Phase I/II clinical trial to study a new bioerodible drug delivery implant for the treatment of glaucoma and hypertension. The implant is designed to provide long-term sustained release of latanoprost, one of the new class of prostaglandin analogs. The drug delivery implant, based on the company’s Durasert technology system, will be injected into the subconjunctival space in the eye (between the sclera and the lower lid), be bioerodible and is expected to deliver its drug for a period of months.
If successful, this implant would solve the problems of non-compliance, the inability by some to administer the drops and, depending on its price, perhaps address the increasing glaucoma medication cost issues.
To read more about this potentially breakthrough technology, please follow this link.
You might also enjoy...
- Eyenovations Developing Contact Lens That Delivers Continuous, Extended Release of Medications; Benefit Seen for Glaucoma Patients
- Can External Drug Delivery System Improve Treatment of Retinal Disease?
- pSivida Corp Presentations at ARVO 2009
- QLT Announces Interim Data for Phase 2 Punctal Plug Delivery System Clinical Trial
- Molteno vs. Ahmed Implants for Treatment of Glaucoma
Jump down to form below to submit your own comments